Intercept: Topline data in Phase 3 cirrhosis/NASH trial pushed to next year

 Study remains ongoing; top-line data anticipated in Q1 2022 versus near the end of the year

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that top-line data from its Phase 3 REVERSE trial will be delayed from our previous guidance of near the end of the year and is now expected in the first quarter of 2022.

https://finance.yahoo.com/news/intercept-pharmaceuticals-provides-phase-3-130000022.html